Activation of CpG-ODN-Induced TLR9 Signaling Inhibited by Interleukin-37 in U937 Human Macrophages
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Interleukin-37 (IL-37) is an anti-inflammatory cytokine that inhibits a broad spectrum of inflammatory responses in various human cells, including neutrophils, macrophages, and endothelial cells. The aim of this study was to identify the role of IL-37 in toll-like receptor 9 (TLR9) signaling in human macrophages. Materials and Methods: Human macrophage U937 cells treated with CpG-oligonucleotides (CpG-ODN), recombinant IL-37, or dexamethasone were used in an in vitro study. IL-37 small interfering RNA (siRNA) and TLR9 siRNA were used to silence endogenous IL-37 and TLR9, respectively. Expression levels of phosphorylated nuclear factor-κB (NF-κB), IκBα, IL-37, IL-1β, tumor necrosis factor-α (TNF-α), and IL-6 protein were assessed by real-time quantitative polymerase chain reaction and Western blotting. CpG-ODN-mediated IL-37 expression stimulated by dexamethasone was detected using immunofluorescent analysis. Results: U937 cells treated with CpG-ODN induced activation of the NF-κB pathway and increased the expression of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6, but reduced that of IL-37. Recombinant IL-37 attenuated phosphorylation of NF-κB and IκBα and the expression of IL-1β, TNF-α, and IL-6 stimulated by CpG-ODN. Human macrophages transfected with IL-37 siRNA augmented the expression of IL-1β, TNF-α, and IL-6 mRNA and protein in cells treated with CpG-ODN. Dexamethasone markedly inhibited expression of pro-inflammatory cytokines in U937 cells, whereas IL-37 expression was increased with the addition of dexamethasone. Inflammatory responses elicited by CpG-ODN were dependent on an MyD88-TRAF6 pathway. IL-37 inhibited CpG-ODN-induced ubiquitination of TRAF6 in U937 macrophages. Conclusion: IL-37 inhibits CpG-ODN-mediated inflammatory responses through regulation of a TRAF6- NF-κB pathway in human macrophages.
Abstract
Purpose: Interleukin-37 (IL-37) is an anti-inflammatory cytokine that inhibits a broad spectrum of inflammatory responses in various human cells, including neutrophils, macrophages, and endothelial cells. The aim of this study was to identify the role of IL-37 in toll-like receptor 9 (TLR9) signaling in human macrophages. Materials and Methods: Human macrophage U937 cells treated with CpG-oligonucleotides (CpG-ODN), recombinant IL-37, or dexamethasone were used in an in vitro study. IL-37 small interfering RNA (siRNA) and TLR9 siRNA were used to silence endogenous IL-37 and TLR9, respectively. Expression levels of phosphorylated nuclear factor-κB (NF-κB), IκBα, IL-37, IL-1β, tumor necrosis factor-α (TNF-α), and IL-6 protein were assessed by real-time quantitative polymerase chain reaction and Western blotting. CpG-ODN-mediated IL-37 expression stimulated by dexamethasone was detected using immunofluorescent analysis. Results: U937 cells treated with CpG-ODN induced activation of the NF-κB pathway and increased the expression of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6, but reduced that of IL-37. Recombinant IL-37 attenuated phosphorylation of NF-κB and IκBα and the expression of IL-1β, TNF-α, and IL-6 stimulated by CpG-ODN. Human macrophages transfected with IL-37 siRNA augmented the expression of IL-1β, TNF-α, and IL-6 mRNA and protein in cells treated with CpG-ODN. Dexamethasone markedly inhibited expression of pro-inflammatory cytokines in U937 cells, whereas IL-37 expression was increased with the addition of dexamethasone. Inflammatory responses elicited by CpG-ODN were dependent on an MyD88-TRAF6 pathway. IL-37 inhibited CpG-ODN-induced ubiquitination of TRAF6 in U937 macrophages. Conclusion: IL-37 inhibits CpG-ODN-mediated inflammatory responses through regulation of a TRAF6- NF-κB pathway in human macrophages.
참고문헌 (28)
- Kumar S, "Identification and initial characterization of four novel members of the interleukin-1 family", J Biol Chem, 275, pp.10308~10314 (2000)
- Dunn E, "Annotating genes with potential roles in the immune system : six new members of the IL-1family", Trends Immunol, 22, pp.533~536 (2001)
- Wang L, "Interleukin-37 : a crucial cytokine with multiple roles in disease and potentially clinical therapy", Oncol Lett, 15, pp.4711~4719 (2018)
- Nold MF, "IL-37 is a fundamental inhibitor of innate immunity", Nat Immunol, 11, pp.1014~1022 (2010)
- Dinarello CA, "Suppression of innate inflammation and immunity by interleukin-37", Eur J Immunol, 46, pp.1067~1081 (2016)
- Takeda K, "Toll-like receptors in innate immunity", Int Immunol, 17, pp.1~14 (2005)
- Kawai T, "The role of pattern-recognition receptors in innate immunity : update on Toll-like receptors", Nat Immunol, 11, pp.373~384 (2010)
- Takeshita F, "Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9", Semin Immunol, 16, pp.17~22 (2004)
- Duffy L, "Toll-like receptors in the pathogenesis of autoimmune diseases : recent and emerging translational developments", Immunotargets Ther, 5, pp.69~80 (2016)
- Nold-Petry CA, "IL-37 requires the receptors IL-18Rα and IL-1R8(SIGIRR)to carry out its multifaceted anti-inflammatory program upon innate signal transduction", Nat Immunol, 16, pp.354~365 (2015)
- Xie Y, "Interleukin-37 suppresses ICAM-1expression in parallel with NF-κB down-regulation following TLR2activation of human coronary artery endothelial cells", Int Immunopharmacol, 38, pp.26~30 (2016)
- Bulau AM, "Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses", Proc Natl Acad Sci U S A, 111, pp.2650~2655 (2014)
- Nørgaard NN, "CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling : effects on myeloma cell apoptosis and in vitro osteoblastogenesis", J Immunol, 185, pp.3131~3139 (2010)
- Zhang C, "CpG-oligodeoxynucleotides may be effective for preventing ionizing radiation induced pulmonary fibrosis", Toxicol Lett, 292, pp.181~189 (2018)
- Zhao PW, "Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis", PLoS One, 9, pp.e95346~ (2014)
- Song L, "Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus", J Clin Immunol, 33, pp.111~117 (2013)
- Chen B, "Interleukin-37is increased in ankylosing spondylitis patients and associated with disease activity", J Transl Med, 13, pp.36~ (2015)
- Charrad R, "Anti-inflammatory activity of IL-37 in asthmatic children : correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL17A", Immunobiology, 221, pp.182~187 (2016)
- Bouali E, "Interleukin-37expression is decreased in Behçet’s disease and is associated with inflammation", Immunol Lett, 167, pp.87~94 (2015)
- Wan ZY, "Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration", Int J Clin Exp Pathol, 7, pp.656~662 (2014)
- Kawai T, "TLR signaling", Semin Immunol, 19, pp.24~32 (2007)
- Kawai T, "Signaling to NF-κB by Toll-like receptors", Trends Mol Med, 13, pp.460~469 (2007)
- Hemmi H, "A toll-like receptor recognizes bacterial DNA", Nature, 408, pp.740~745 (2000)
- Wan Y, "The dual functions of IL-1 receptor-associated kinase 2 in TLR9-mediated IFN and proinflammatory cytokine production", J Immunol, 186, pp.3006~3014 (2011)
- An H, "Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-κB, ERK and p38 MAPK signal pathways", Immunol Lett, 81, pp.165~169 (2002)
- Barrat FJ, "Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus", J Exp Med, 202, pp.1131~1139 (2005)
- Farina A, "Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma", J Invest Dermatol, 134, pp.954~964 (2014)
- Spachidou MP, "Expression of functional Toll-like receptors by salivary gland epithelial cells : increased mRNA expression in cells derived from patients with primary Sjögren’s syndrome", Clin Exp Immunol, 147, pp.497~503 (2007)